Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is indicated for passive immunization against hepatitis B virus in specific clinical situations.

• Post‑exposure prophylaxis for individuals with recent exposure to hepatitis B surface antigen‑positive blood or body fluids.
• Prevention of hepatitis B infection in newborns of hepatitis B‑positive mothers when administered within 12 hours of birth.
• Supplementation of hepatitis B vaccine in persons with compromised immune response.
• Use in patients undergoing liver transplantation to reduce the risk of HBV recurrence.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin preparations.

Common

• Mild fever or chills shortly after infusion.
• Headache or fatigue.
• Localized injection site redness or swelling.
• Nausea or mild gastrointestinal discomfort.

Serious

• Severe allergic reaction or anaphylaxis.
• Acute hemolysis.
• Renal impairment or acute kidney injury.
• Thromboembolic events such as deep vein thrombosis.

When prescribing Hepatect Cp, clinicians should consider several precautionary measures to ensure safe administration.

• Assess patient history for prior hypersensitivity to blood products or immunoglobulins.
• Monitor vital signs during and after infusion for signs of reaction.
• Adjust infusion rate in patients with cardiovascular disease or compromised circulation.
• Use caution in individuals with renal insufficiency or a history of kidney disease.
• Avoid use in patients with known IgA deficiency who have anti‑IgA antibodies.
• Evaluate hepatitis B serology to confirm need for passive immunization.

Hepatect Cp may interact with other medications or medical conditions, requiring attention to avoid adverse outcomes.

Avoid

• Concurrent administration of other blood‑derived products without appropriate monitoring.
• Simultaneous infusion of high‑dose intravenous immunoglobulin preparations.

Use with caution

• Live vaccines administered within 3 months of Hepatect Cp due to potential interference with immune response.
• Anticoagulants, as immunoglobulin infusions can affect coagulation parameters.
• Diuretics in patients with renal impairment, because of fluid balance considerations.
• Cytotoxic chemotherapy agents, which may increase risk of renal toxicity.